Anlon Healthcare has completed the acquisition of 67.48% equity shareholding of Apiqo Organics on January 9, 2026. Consequent to this acquisition, Apiqo Organics has become a subsidiary of the company. The acquisition of the Apiqo Organics will significantly enhances the company’s vertical integration, secures critical supply of high-quality intermediates, increases additional 700 to 800 MT annual manufacturing capacity for advanced pharmaceutical intermediates, and strengthens the ability of the company to deliver reliable, cost-effective solutions to its global pharmaceutical partners.
Earlier, the company had entered into a Share Purchase Agreement (SPA) with Apiqo Organics (formerly known as M/s Apple Life Science, a partnership firm) for the same.
Anlon Healthcare is a chemical manufacturing company engaged in manufacturing of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), which are supplied to customers both in India and international markets.
